Drug intelligence / Profile preview

docetaxel + SHR1020

Development stage: Preclinical
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Intravenous

Overview

Docetaxel is a taxane-class antineoplastic agent used in the treatment of various cancers, including breast, lung, prostate, stomach, and head and neck cancers. It works by promoting the assembly of microtubules from tubulin dimers and stabilizing them against depolymerization, thereby inhibiting cell division and leading to cancer cell death. Docetaxel is administered intravenously. SHR1020 is an investigational drug; while specific details about its mechanism are not available in the provided sources, it is being studied in combination with docetaxel for potential synergistic effects in oncology indications.

Other names: None

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on docetaxel + SHR1020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + SHR1020.

Explore the full profile